KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Liabilities (2018 - 2025)

Amneal Pharmaceuticals has reported Total Liabilities over the past 8 years, most recently at $3.7 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $3.7 billion for Q4 2025, up 3.83% from a year ago — trailing twelve months through Dec 2025 was $3.7 billion (up 3.83% YoY), and the annual figure for FY2025 was $3.7 billion, up 3.83%.
  • Total Liabilities for Q4 2025 was $3.7 billion at Amneal Pharmaceuticals, up from $3.7 billion in the prior quarter.
  • Over the last five years, Total Liabilities for AMRX hit a ceiling of $3.9 billion in Q2 2022 and a floor of $3.5 billion in Q4 2023.
  • Median Total Liabilities over the past 5 years was $3.6 billion (2021), compared with a mean of $3.6 billion.
  • Biggest five-year swings in Total Liabilities: fell 9.88% in 2021 and later increased 6.49% in 2022.
  • Amneal Pharmaceuticals' Total Liabilities stood at $3.6 billion in 2021, then grew by 1.19% to $3.6 billion in 2022, then decreased by 4.5% to $3.5 billion in 2023, then increased by 4.58% to $3.6 billion in 2024, then increased by 3.83% to $3.7 billion in 2025.
  • The last three reported values for Total Liabilities were $3.7 billion (Q4 2025), $3.7 billion (Q3 2025), and $3.5 billion (Q2 2025) per Business Quant data.